|
Japan Leukemia Articles
Japan Leukemia News : SymBio and Eisai to Launch Symbenda(R) in Singapore for the Treatment of Low-grade Non-Hodgkin's Lymphoma and Chronic ... Tue, 07 Sep 2010 19:24:53 GMT NEW YORK (GenomeWeb News) – The National Institutes of Health will provide $161.3 million in funding to expand a nationwide effort to advance personalized medicine through the use of pharmacogenomics, NIH said today.Japan Leukemia News : Research and Markets: Epigenetics Therapeutics to 2017 - High Market Potential for Epigenetics Drugs in Acute Myeloid ... Mon, 06 Sep 2010 14:30:37 GMT DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/f7e7a7/epigenetics_therap) has announced the addition of the "Epigenetics Therapeutics to 2017 - High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma" report to their offering. Epigenetics Therapeutics to 2017 - High ...Research and Markets: Epigenetics Therapeutics to 2017 - High Market Potential for Epigenetics Drugs in Acute Myeloid ... Mon, 06 Sep 2010 14:21:00 GMT DUBLIN----Research and Markets has announced the addition of the "Epigenetics Therapeutics to 2017 - High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma" report to their offering.CytRx Initiates Phase 2 Clinical Trial with Bafetinib in Advanced Prostate Cancer Tue, 07 Sep 2010 12:46:21 GMT LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical company specializing in oncology, today announced initiation of the PROstate Advanced Cancer Treatment (PROACT) Phase 2 proof-of-concept clinical trial to evaluate the efficacy and safety of bafetinib in patients with advanced prostate cancer. The open-label PROACT trial is being conducted at City of Hope, located ...CytRx Initiates Phase 2 Clinical Trial with Bafetinib in Advanced Prostate Cancer Tue, 07 Sep 2010 12:30:00 GMT LOS ANGELES----CytRx Corporation , a biopharmaceutical company specializing in oncology, today announced initiation of the PROstate Advanced Cancer Treatment Phase 2 proof-of-concept clinical trial to evaluate the efficacy and safety of bafetinib in patients with advanced prostate cancer.Celgene Officially Notified Of ANDA Filing For REVLIMID(R) Mon, 06 Sep 2010 14:41:35 GMT Celgene Corporation (NASDAQ: CELG) announced it has received a Paragraph IV Certification Letter advising that Natco Pharma Limited of Hyderabad, India, submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA). The application requests authorization to manufacture and market generic versions of REVLIMID® (lenalidomide) 5, 10, 15 and 25 mg capsules in ...Stratfield test scandal inspires novel by school's pyschologist Mon, 06 Sep 2010 20:05:20 GMT The front cover of Dear Whistleblower, a mystery suspense novel written by Joan Rooney Riccitelli, a school psychologist in Fairfield for 30-plus years.OBITUARIES Mon, 06 Sep 2010 07:36:42 GMT Robert Fischer SPRINGFIELD — Robert “Bruce” Fischer of Springfield died Sept. 1 of age-related causes at age 84. No service is planned. He was born Oct. 30, 1925, in Eugene to John and Louise Nielsen Fischer. He married Darleen Hayes on June 23, 1950, in Eugene. She died Dec. 29, …Epigenetics Therapeutics to 2017 - High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple ... Thu, 02 Sep 2010 11:29:00 GMT ReportsandReports announces it will carry the Epigenetics Therapeutics to 2017 - High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma Market Research Report in its store.Novartis Drug Tasigna® Approved In Switzerland After Fast-track Review For Treatment Of Patients With Newly Diagnosed ... Thu, 02 Sep 2010 13:41:51 GMT The Swiss health authority Swissmedic has granted approval for Tasigna® (nilotinib) 300 mg twice daily for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Tasigna is the first new therapeutic option for newly diagnosed patients since the introduction of Glivec® (imatinib), providing a major advance for ...Celgene receives Paragraph IV Certification Letter on submission of ANDA for REVLIMID Fri, 03 Sep 2010 12:13:12 GMT Celgene Corporation today announced it has received a Paragraph IV Certification Letter advising that Natco Pharma Limited of Hyderabad, India, submitted an Abbreviated New Drug Application to the U.S. Food and Drug Administration. The application requests authorization to manufacture and market generic versions of REVLIMID (lenalidomide) 5, 10, 15 and 25 mg capsules in the United States.Researchers identify two proteins in cellular response to mechanical stimulation Fri, 03 Sep 2010 08:12:12 GMT Scripps Research Institute scientists have identified two proteins with potential to be important targets for research into a wide range of health problems, including pain, deafness, and cardiac and kidney dysfunction.Most with Asperger's adjust to life's demands Thu, 02 Sep 2010 12:56:00 GMT Dear Dr. Donohue: Will you write about Asperger’s disorder? Local student wins scholarship Wed, 01 Sep 2010 19:07:07 GMT An Edmonton student advocating for sustainable transportation was one of just four Canadians to take home a $2,500 ECO Canada scholarship last month.[...] |
Infectious and parasitic diseases |
|
|
< Home > |
||